Attached files
| file | filename |
|---|---|
| EX-10.24 - EXHIBIT 10.24 - INVIVO THERAPEUTICS HOLDINGS CORP. | tm2032415d4_ex10-24.htm |
| EX-5.1 - EXHIBIT 5.1 - INVIVO THERAPEUTICS HOLDINGS CORP. | tm2032415d4_ex5-1.htm |
| EX-4.14 - EXHIBIT 4.14 - INVIVO THERAPEUTICS HOLDINGS CORP. | tm2032415d4_ex4-14.htm |
| EX-4.13 - EXHIBIT 4.13 - INVIVO THERAPEUTICS HOLDINGS CORP. | tm2032415d4_ex4-13.htm |
| EX-4.12 - EXHIBIT 4.12 - INVIVO THERAPEUTICS HOLDINGS CORP. | tm2032415d4_ex4-12.htm |
| S-1/A - S-1/A - INVIVO THERAPEUTICS HOLDINGS CORP. | tm2032415-3_s1a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in this Amendment No. 1 to the Registration Statement (No. 333-249353) on Form S-1 and related Prospectus of InVivo Therapeutics Holdings Corp. of our report dated February 20, 2020, relating to the consolidated financial statements of InVivo Therapeutics Holdings Corp. and subsidiary, appearing in the Annual Report on Form 10-K of InVivo Therapeutics Holdings Corp. for the year ended December 31, 2019.
We also consent to the reference to our firm under the heading "Experts" in such Prospectus.
/s/ RSM US LLP
Boston, Massachusetts
October 16, 2020
1